期刊文献+

晚期复发性卵巢上皮性癌的再治疗 被引量:1

Secondary Therapy of Advanced Palindromic Ovarian Epithelial Carcinoma
下载PDF
导出
摘要 目的 :探讨晚期复发性卵巢上皮癌再治疗的方法。方法 :回顾性分析 1996- 2 0 0 1年住院治疗的晚期复发性卵巢癌病例共 5 6例临床资料。卵巢浆液性癌 2 6例 ,黏液性癌 19例 ,宫内膜样癌 10例 ,转移性腺癌 1例。基本治疗原则仍是以手术为主联合术前术后的化疗。结果 :截至 2 0 0 2年 5月全部随访 ,死亡 2 3例 ,现存活 33例。已死亡者平均生存时间为 18 5个月。总的 3年生存率为 2 7 5 % ( 6/ 2 2 ) ,其中泰素类用药组为 4 / 12。拓扑替康组共 8例 ,其有效率为 3/ 8。结论 :1)紫杉醇 +顺铂的联合化疗可成为晚期复发性卵巢癌再治疗的首选。 2 )拓扑替康联合化疗是复发性卵巢癌有效的补救治疗手段 ,值得推广应用。 3) Objctive To study the method of secondary therapy in patients with advanced palindromic ovarian epithelial carcinoma.Methods The clinical data of 56 patients with advanced palindromic ovarian epithelial carcinoma hospitalized from 1996 to 2001 were reviewed and analyzed retrospectively,including 26 serous carcinoma,19 mucinous carcinoma,10 endometriod carcinoma and 1 metastatic adenocarcinoma.Operation combined with preoperative and postoperative chemotherapy was the primary therapeutic principle.Results By May 2002,23 women were dead,33 were survival.The mean survival time was 18.5 months while the overall 3-year survival rate was 27.5%(6/22),including 4(4/12) cases treated with taxol and 8 cases with topotecan whose effective rate was 3/8.Conclusions 1)The combined chemotherapy with TP regimen (Taxol+DDP) is the first-line treatment in advanced palindromic ovarian epithelial carcinoma.2)The combination chemotherapy with toptecan is a prospective method,which is the effective remedial therapy.3)The reoperation is still the significant therapeutic method in advanced palindromic ovarian epithelial carcinoma.
出处 《肿瘤防治杂志》 2003年第4期407-409,共3页 China Journal of Cancer Prevention and Treatment
关键词 卵巢肿瘤 外科学 药物疗法 综合疗法 再治疗 晚期复发性卵巢上皮癌 ovarian neoplasms/surgery ovarian neoplasms/drug therapy combined modality therapy
  • 相关文献

参考文献1

二级参考文献2

  • 1Ten Bokkel Huinink W,Gore M,Carmichael J,et al.Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer[].Journal of Clinical Oncology.1997
  • 2Eisenhauer EA,Ten Bokkel Huinink WW,Swenerton KD,et al.European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion[].Journal of Clinical Oncology.1994

共引文献6

同被引文献10

  • 1朱笕青,高永良,陈雅卿,陈鲁,刘兰芳.吉西他滨加顺铂治疗复发性卵巢癌[J].中国癌症杂志,2005,15(2):173-175. 被引量:7
  • 2Parmar MK, Ledermann JA, Colombo N, et al. Paelitaxel plus platinum-based chemotherapy versus conventional platinum based chemtherapy in women with relapsed ovarian cancer: the ICON4/AGO-0VAR-2.2 trial [ J ] . Lancet, 2003, 361(9375): 2099-2106.
  • 3Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview [ J ] . Cancer, 1997, 80(7): 1273- 1283.
  • 4Bray F, Loos AH, Toggnazzo S, et al. Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000 [ J ] . Int J Cancer, 2005, 113(6): 977-990.
  • 5Pfisterer J, Plante M, Vergote I, et al. AGO-OVAR; NCIC CTG, EORTC GCG. Gemcitabine/carboplatin(GC) vs. carboplatin(C) in platinum sensitive recurrent ovarian cancer(OVCA) [ J ] . J Clin Oncol, 2006, 24(29): 4699-4707.
  • 6Pignata S, Breda E, Scambia G, et al. A phase Ⅱ study of weekly carboplatin and paclitaxel'as first-line treatment of elderly patients with advanced ovarian cancer: A Multicentre Italian Trial in Ovarian cancer(MITO-5)study [ J ] . Crit Rev Oncol Hematol, 2008, 66(3): 229-236.
  • 7Harter P, Bois A, Hahmann M, et al. Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee; AGO Ovarian Cancer Study Group Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie(AGO) DESKTOP OVAR trial [ J ] . Ann Surg Oncol, 2006, 13(12): 1702-1710.
  • 8孟庆伟,赵晓东,张毅,李晓红.老年卵巢癌患者对手术和术后辅助化疗耐受性的分析[J].中华老年医学杂志,2008,27(2):111-113. 被引量:6
  • 9杨悦.多帕菲联合铂类治疗复发转移性卵巢癌58例临床分析[J].中华肿瘤防治杂志,2008,15(15):1176-1177. 被引量:10
  • 10潘凌亚,黄惠芳,连利娟,朱馥丽,黄荣丽,沈铿,吴鸣,郎景和.70岁以上患者妇科恶性肿瘤的手术治疗[J].中华妇产科杂志,2001,36(10):614-617. 被引量:21

引证文献1

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部